# RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC

> **NCT04849377** · PHASE2 · WITHDRAWN · sponsor: **Icahn School of Medicine at Mount Sinai**

## Conditions studied

- Human Papillomavirus (HPV)
- Head and Neck Squamous Cell Carcinoma (HNSCC)

## Interventions

- **RADIATION:** RT 50 Gy
- **RADIATION:** RT 54 GY
- **RADIATION:** RT 60 GY
- **OTHER:** Induction Therapy
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin 200
- **DRUG:** Cisplatin 240

## Key facts

- **NCT ID:** NCT04849377
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-06-14
- **Primary completion:** 2022-06-14
- **Final completion:** 2022-06-14
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** lack of eligible participants due to change in study criterias
- **Last updated:** 2022-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04849377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04849377, "RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04849377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*